AstraZeneca India Gets Approval To Market Drug Treating Breast Cancer

AstraZeneca India, a pharmaceutical company, announced on Friday that the Drugs Controller General of India had given the go-ahead to commercialise its medication for the treatment of breast cancer.

In adults with early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy, the Drugs Controller General of India (DCGI) has approved Lynparza (olaparib) as a monotherapy. According to a statement from AstraZeneca India, the clearance was based on findings from the OlympiA Phase III trial that found Olaparib showed a statistically significant and clinically significant improvement, with a benefit to overall survival.

With the DCGI’s approval, Lynparza is now recognised for the treatment of early-stage breast cancer in the US, EU, Japan, India, and a number of other nations, it was said.

The only licenced medication that specifically targets BRCA (Breast Cancer gene) mutations in early-stage breast cancer is Lynparza.

The regulatory approval of Lynparza, according to AstraZeneca India Managing Director and Country President Gagandeep Singh, “reinforces our growing strengths in innovation and clinical research for providing comprehensive solutions for cancer therapy in India.”

With an estimated 23 lakh cases reported each year, breast cancer is one of the most common cancers in the world.

Picture Courtesy: google/images are subject to copyright